Madrigal Pharmaceuticals, Inc.
MDGLNASDAQHealthcare● Active
$471.43
$-15.56(-3.19%)
Market Cap$10.9B
P/E Ratio—
52W High$615
52W Low$271.96
Madrigal Pharmaceuticals, Inc. (MDGL) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · MDGL · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.96B | $0.18B | $0.00B | $0.00B | $0.00B |
| Cost of Revenue | $0.06B | $0.01B | $0.00B | $0.00B | $0.00B |
| Gross Profit | $0.90B | $0.17B | $0.00B | $0.00B | $0.00B |
| Gross Margin %(computed) | 94.14% | 96.54% | — | — | — |
| Operating Expenses | |||||
| R&D Expenses | $0.39B | $0.24B | $0.27B | $0.25B | $0.21B |
| G&A Expenses | $0.00B | $0.00B | $0.11B | $0.05B | $0.04B |
| Total Operating Expenses | $1.20B | $0.67B | $0.38B | $0.29B | $0.24B |
| Operating Income | ($0.30B) | ($0.50B) | ($0.38B) | ($0.29B) | ($0.24B) |
| Operating Margin %(computed) | -31.31% | -276.39% | — | — | — |
| Interest Income | $0.04B | $0.05B | $0.02B | $0.00B | $0.00B |
| Interest Expense | $0.02B | $0.01B | $0.01B | $0.00B | $0.00B |
| Income Before Tax | ($0.29B) | ($0.47B) | ($0.37B) | ($0.30B) | ($0.24B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | ($0.29B) | ($0.47B) | ($0.37B) | ($0.30B) | ($0.24B) |
| Net Margin %(computed) | -30.08% | -258.64% | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-12.85 | $-21.90 | $-19.99 | $-17.23 | $-14.63 |
| Wtd Avg Shares | 0.02B | 0.02B | 0.02B | 0.02B | 0.02B |
| EBITDA | ($0.26B) | ($0.45B) | ($0.36B) | ($0.29B) | ($0.24B) |
| EBITDA Margin %(computed) | -27.59% | -249.88% | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Madrigal Pharmaceuticals, Inc. data
About Madrigal Pharmaceuticals, Inc. (MDGL) Income Statement
Madrigal Pharmaceuticals, Inc. (MDGL) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, MDGL reported revenue of $0.96B, gross profit of $0.90B (gross margin 94.14%), and net income of ($0.29B) — a net profit margin of -30.08%.
Frequently asked questions
MDGL · 4 questionsMadrigal Pharmaceuticals, Inc. (MDGL) reported revenue of $0.96B for 2025, up 432.1% year-over-year.
MDGL revenueMDGL salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08